Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

Hey Turks, the Pro-Neura probuphine patent actually expires in April 2024.
In terms of competition for probuphine, I think it will all depend on how successful it eventually becomes. Anything less than $50 million in sales per year, and I doubt anyone will enter the market. If it is successful, then anyone filing an ANDA for a generic will not be allowed to use the 505(b)(2) pathway...requiring full Phase 3 trials.

Plus, Titan has another patent application pending on improvements to the entire ProNeura system (for use with any drug) that would not expire until 2031 if granted.

Also, Titan has a ProNeura-Parkinson's patent, which may turn out to be a whole lot more lucrative than opioid abuse given the challenging reimbursement environment, that doesn't expire until 2032.